开立医疗(300633.SZ)：2020年度由盈转亏 预亏2932万元–5732万元
格隆汇 1 月 29日丨开立医疗(300633.SZ)披露2020年度业绩预告，预计2020年度归属于上市公司股东的净亏损2932.00万元–5732.00万元，上年同期盈利1.02亿元；扣除非经常性损益后的净亏损8970.00万元–1.18亿元，上年同期盈利7317.69万元。2020年度归属于上市公司股东的净利润与上年同期相比出现亏损，主要原因如下：
(一)计提商誉减值准备
报告期内，上海威尔逊光电仪器有限公司及上海和一医疗仪器有限公司(以下简称威尔逊)2020年经营业绩未达预期，根据《会计监管风险提示第8号-商誉减值》及《企业会计准则第8号-资产减值》的相关要求，公司对所有包含商誉的资产组进行初步减值测试后，拟计提商誉减值准备1.96亿元–2.1亿元。
剔除商誉减值及相关因素影响，2020年公司实现归属于上市公司股东的净利润预计为1.33亿元–1.47亿元，较2019年剔除商誉减值后的净利润1.22亿元有所增长。
公司商誉减值准备实际计提金额需根据评估机构的评估报告及会计师事务所审计数据确定。
(二)2020年度公司业务情况2020年，公司努力克服新冠疫情对公司经营的负面影响，国内方面，一季度疫情严重时期对国内业务影响较大，随着国内疫情得到控制，公司国内业务逐渐恢复，全年实现国内业务收入的正增长，国内内镜设备业务仍取得较高增速；国际方面，由于疫情在国外持续蔓延，国际业务未恢复到正常水平，国际业务收入下滑较大。总体来看，受疫情影响，公司全年业务收入有所下滑，但疫情期间因减少出差和展会参与等活动，销售费用明显减少，公司彩超产品毛利率水平稳定，内镜产品毛利率显著增长，导致整体毛利率有所上升，最终实现剔除商誉减值及相关因素影响后的净利润正增长。
(三)非经常性损益影响
报告期内，非经常性损益对归属于母公司净利润的影响金额预计为6038.00万元，为公司取得的政府补助资金、理财产品收益等，上年同期非经常性损益对归属于母公司净利润的影响金额为2836.00万元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
